Publicaties
Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool KU Leuven
Research autopsy programmes in oncology: shared experience from 14 centres across the world KU Leuven
An interpretative phenomenological analysis of the lived experience of people with multimorbidity in low- and middle-income countries Instituut voor Tropische Geneeskunde Universiteit Antwerpen
Alternative splicing expands the clinical spectrum of NDUFS6-related mitochondrial disorders Universiteit Antwerpen Vlaams Instituut voor Biotechnologie
Association between exposure to multiple air pollutants, transportation noise and cause-specific mortality in adults in Switzerland Vrije Universiteit Brussel
Background: Long-term exposure to air pollution and noise is detrimental to health; but studies that evaluated both remain limited. This study explores associations with natural and cause-specific mortality for a range of air pollutants and transportation noise. Methods: Over 4 million adults in Switzerland were followed from 2000 to 2014. Exposure to PM2.5, PM2.5 components (Cu, Fe, S and Zn), NO2, black carbon (BC) and ozone (O3) from ...
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition Vrije Universiteit Brussel
INTRODUCTION: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy for solitary progression in melanoma.
PATIENTS AND METHODS: Patients with metastatic melanoma treated with ICI between 2010 and 2019 with solitary progression as first progressive event ...
Network integration and modelling of dynamic drug responses at multi-omics levels KU Leuven
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program Vrije Universiteit Brussel
Given the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of patients who received dabrafenib in a compassionate use setting through the Named Patient Program (DESCRIBE I study) during December 2010-August 2013 in Europe, New Zealand and Australia. Of the 331 ...